Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
AuthorCoyle, L; Morley, NJ; Rambaldi, A; Mason, KD; Verhoef, G; Furness, CL; Zhang, A; Jung, AS; Cohan, D; Franklin, JL
Source TitleLeukemia and Lymphoma
PublisherTAYLOR & FRANCIS LTD
University of Melbourne Author/sMason, Kylie
AffiliationSir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsCoyle, L., Morley, N. J., Rambaldi, A., Mason, K. D., Verhoef, G., Furness, C. L., Zhang, A., Jung, A. S., Cohan, D. & Franklin, J. L. (2020). Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 61 (9), pp.2103-2112. https://doi.org/10.1080/10428194.2020.1759055.
Access StatusAccess this item via the Open Access location
Open Access URLhttp://doi.org/10.1080/10428194.2020.1759055
The phase 2 portion of this open-label phase 2/3 study assessed the efficacy and safety of blinatumomab as second salvage for aggressive relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) following platinum-based first salvage chemotherapy. Forty-one patients with aggressive disease (32% relapsed; 68% refractory) enrolled and received stepwise blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2; 19 (46%) completed cycle 1 and 3 (7%) completed cycle 2. The overall response rate after 12 weeks was 37%, including 9 (22%) complete metabolic responses. Eight (20%) patients (all responders) subsequently received stem cell transplants. Grade ≥3 adverse events were reported in 29 (71%) patients. Grade 3 cytokine release syndrome occurred in one patient. Grade 3 neurologic events occurred in 10 (24%) patients; all resolved. Blinatumomab monotherapy appears effective as second salvage therapy in patients with r/r aggressive B-NHL. Trial registration: NCT02910063.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References